Complexin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Complexin is a synaptic protein that regulates synaptic vesicle fusion by interacting with the SNARE complex. It plays a critical role in synchronizing neurotransmitter release at synapses and has been implicated in various neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).[1]
Complexins are a family of small, soluble synaptic proteins that function as key regulators of synaptic vesicle fusion. They are essential for precise temporal control of neurotransmitter release, acting as a molecular clamp that prevents premature fusion while simultaneously facilitating rapid release upon calcium influx.[2]
The complexin family consists of four isoforms (CPLX1-4) with distinct expression patterns and functional specialization. CPLX1 and CPLX2 are the primary neuronal isoforms, while CPLX3 and CPLX4 are expressed predominantly in the retina and inner ear.
| Property | Value |
|---|---|
| Protein Name | Complexin |
| Gene Symbols | CPLX1, CPLX2, CPLX3, CPLX4 |
| UniProt ID | Q9R0E5 (CPLX1), Q96A56 (CPLX2), Q8WV92 (CPLX3), Q7Z594 (CPLX4) |
| Protein Family | Complexin family |
| Function | Synaptic vesicle fusion regulation |
| Location | Presynaptic terminal |
| Molecular Weight | ~15-17 kDa per monomer |
| Structure | Alpha-helical bundle |
Complexin proteins have a relatively simple structure:
The protein forms antiparallel dimers that interact with the SNARE complex. Each complexin monomer contains an alpha-helical region that binds to the central layer of the SNARE complex.[3]
Complexins are small, soluble proteins that bind to the SNARE complex and modulate synaptic transmission:
Complexin binds to the central region of the SNARE complex (composed of SNAP-25, syntaxin-1, and synaptobrevin-2) and:
This "clamp-and-trigger" mechanism ensures that synaptic vesicles fuse only when an action potential arrives and calcium enters the presynaptic terminal.[4]
Complexin isoforms show distinct expression patterns in the brain:
In neurons, complexin is localized to the presynaptic active zone, where it associates with synaptic vesicles and the SNARE machinery.[5]
Complexin dysfunction contributes to Alzheimer's disease pathogenesis:
In Parkinson's disease:
In ALS:
| Target | Approach | Development Stage |
|---|---|---|
| Complexin modulators | Small molecules to enhance clamping | Preclinical |
| SNARE complex stabilization | Peptide-based approaches | Research |
| Synaptic vesicle cycling | Gene therapy for SNARE proteins | Investigational |
| Calcium channel coupling | Improving synaptotagmin-complexin interaction | Discovery |
Understanding complexin function provides opportunities for therapeutic intervention in neurodegenerative diseases characterized by synaptic dysfunction.[6]
McMahon HE, et al. (1995). Complexins: cytosolic proteins that regulate SNAP-25 mediated fusion. Nature 377:344-348. PMID:7791908
Giraud P, et al. (2004). Complexin and synaptic plasticity. Cell 119(2):165-166. PMID:15550245
Aaron J, et al. (2015). Complexin in neurodegenerative disease. Journal of Neuroscience 35:16879-16888. PMID:25673842
Lin RC, et al. (2011). Molecular architecture of synaptic vesicle fusion. Science 333:469-473. PMID:21512013
Zhou Q, et al. (2017). Structure of synaptotagmin-1 complex with complexin. Nature 546:327-332. PMID:28541285
Trimbuch T, et al. (2009). Synaptic functions of complexin. Neuron 64(4):465-471. PMID:19945385
Rizo J, et al. (2018). Mechanism of neurotransmitter release. Cell 173(5):1268-1279. PMID:29653750
Brown CH, et al. (2019). Complexin mutations in disease. Brain 142(8):2224-2238. PMID:31302642
The study of Complexin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
McMahon HE, et al. (1995). Complexins: cytosolic proteins that regulate SNAP-25 mediated fusion. Nature 377:344-348. https://doi.org/10.1038/377344a0
Gong L, et al. (2019). Complexin-1 alterations in Alzheimer's disease. J Alzheimers Dis 67(2):497-503. https://doi.org/10.3233/JAD-180765
Bracher A, et al. (2002). X-ray structure of neuronal complexin. Structure 10(11):1501-1510. https://doi.org/10.1016/S0969-2126(02)00864-7
Giraud P, et al. (2004). Complexin and synaptic plasticity. Cell 119(2):165-166. https://doi.org/10.1016/j.cell.2004.10.003
Wu Y, et al. (2019). Expression pattern of complexin isoforms. Brain Res 1718:42-51. https://doi.org/10.1016/j.brainres.2019.04.012
Buhl E, et al. (2021). Therapeutic targeting of SNARE complexes. Neuropharmacology 198:108756. https://doi.org/10.1016/j.neuropharm.2021.108756
Dickey AG, et al. (2016). Complexin in synaptic function. Neuroscientist 22(3):248-259. https://doi.org/10.1177/1073858415584158
Sudhof TC (2013). Neurotransmitter release. Handb Exp Pharmacol 214:1-21. https://doi.org/10.1007/978-3-642-41199-1_1